Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Chemotherapy for Advanced Colorectal Cancer
Public ClinicalTrials.gov record NCT00940316. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized Phase II Study of Dual Epidermal Growth Factor Receptor Inhibition With Erlotinib and Panitumumab With or Without Irinotecan as Second Line Therapy in Patients With Metastatic Colorectal Cancer
Study identification
- NCT ID
- NCT00940316
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Northwestern University
- Other
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Interventions
- erlotinib hydrochloride Drug
- irinotecan hydrochloride Drug
- panitumumab Biological
Drug · Biological
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 17, 2010
- Primary completion
- Dec 31, 2014
- Completion
- Dec 31, 2014
- Last update posted
- May 6, 2019
2010 – 2015
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer Care & Hematology Specialists of Chicagoland | Arlington Heights | Illinois | 60005 | — |
| Northwestern University, Northwestern Medical Faculty Foundation | Chicago | Illinois | 60611-3013 | — |
| Hematology/Oncology Associates | Chicago | Illinois | 60611 | — |
| Joliet Oncology-Hematology Associates, Ltd. | Joliet | Illinois | 60435 | — |
| Hope Cancer Center | Terre Haute | Indiana | 47802 | — |
| Cancer Center of Kansas | Wichita | Kansas | 67214 | — |
| Nebraska Methodist Hospital | Omaha | Nebraska | 68114 | — |
| Virtua Memorial (Regional Cancer Care Associates of Mount Holly) | Mount Holly | New Jersey | 08060 | — |
| Mercy Clinic Oncology and Hematology | Oklahoma City | Oklahoma | 73120-9309 | — |
| The Jones Clinic | Germantown | Tennessee | 38138 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00940316, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 6, 2019 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00940316 live on ClinicalTrials.gov.